Literature DB >> 7333346

Plasma and salivary pharmacokinetics of caffeine in man.

R Newton, L J Broughton, M J Lind, P J Morrison, H J Rogers, I D Bradbrook.   

Abstract

Plasma and salivary caffeine concentrations were measured by gas-liquid chromatography in 6 healthy caffeine-free volunteers following oral administration of 50, 300, 500 and 750 mg caffeine. Caffeine was also given to a single subject intravenously in doses of 300, 500 and 750 mg. Caffeine was rapidly absorbed and was completely available at all doses. The apparent first-order elimination rate constant decreased linearly with dose and was 0.163 +/- 0.081 h-1 for 50 mg and 0.098 +/- 0.027 h-1 for 750 mg. The total body clearance was unaffected by dose and was 0.98 +/- 0.38 ml/min/kg. There was a trend towards increasing apparent volume of distribution with increasing dose. A linear relationship existed between the area under the plasma concentration, time curve and dose and dose-normalised plasma concentration, time plots were superimposable. These findings suggest that caffeine obeys linear pharmacokinetics over the dose range investigated. Despite significant inter-individual differences in pharmacokinetic parameters there was good reproducibility within 5 subjects given 300 mg caffeine orally on 3 occasions. Salivary caffeine levels probably reflect the unbound plasma caffeine concentration and can be used to estimate the pharmacokinetic parameters of the drug. Overall the saliva/plasma concentration ratio was 0.74 +/- 0.08 but within subjects some time-dependence of the ratio was found with higher ratios initially (even after intravenous administration) and lower ratios at longer time intervals after the dose. Urinary elimination of caffeine was low and independent of dose: 1.83% of the dose was eliminated unchanged.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7333346     DOI: 10.1007/bf00609587

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  24 in total

1.  Dose-dependent kinetics of theophylline disposition in asthmatic children.

Authors:  M Weinberger; E Ginchansky
Journal:  J Pediatr       Date:  1977-11       Impact factor: 4.406

2.  Stimulation of caffeine metabolism in the rat by 3-methylcholanthrene.

Authors:  A Aldridge; W D Parsons; A H Neims
Journal:  Life Sci       Date:  1977-10-01       Impact factor: 5.037

3.  Use of saliva in therapeutic drug monitoring.

Authors:  M G Horning; L Brown; J Nowlin; K Lertratanangkoon; P Kellaway; T E Zion
Journal:  Clin Chem       Date:  1977-02       Impact factor: 8.327

4.  Effect of Aroclor 1254, phenobarbital, and polycyclic aromatic hydrocarbons on the plasma clearance of caffeine in the rat.

Authors:  R M Welch; S Y Hsu; R L DeAngelis
Journal:  Clin Pharmacol Ther       Date:  1977-11       Impact factor: 6.875

5.  Psychotropic effects of caffeine in man. IV. Quantitative and qualitative differences associated with habituation to coffee.

Authors:  A Goldstein; S Kaizer; O Whitby
Journal:  Clin Pharmacol Ther       Date:  1969 Jul-Aug       Impact factor: 6.875

6.  Evaluation of the teratogenic potential of fresh-brewed coffee and caffeine in the rat.

Authors:  P E Palm; E P Arnold; P C Rachwall; J C Leyczek; K W Teague; C J Kensler
Journal:  Toxicol Appl Pharmacol       Date:  1978-04       Impact factor: 4.219

7.  Influence of methylxanthine-containing foods on theophylline metabolism and kinetics.

Authors:  T J Monks; J Caldwell; R L Smith
Journal:  Clin Pharmacol Ther       Date:  1979-10       Impact factor: 6.875

8.  The effect of coffee on the function of the sympatho-adrenomedullary system in man.

Authors:  L Levi
Journal:  Acta Med Scand       Date:  1967-04

9.  Studies on theobromine disposition in normal subjects. Alterations induced by dietary abstention from or exposure to methylxanthines.

Authors:  D D Drouillard; E S Vesell; B H Dvorchik
Journal:  Clin Pharmacol Ther       Date:  1978-03       Impact factor: 6.875

10.  Effect of smoking on caffeine clearance.

Authors:  W D Parsons; A H Neims
Journal:  Clin Pharmacol Ther       Date:  1978-07       Impact factor: 6.875

View more
  30 in total

Review 1.  Caffeine and endurance performance.

Authors:  M A Tarnopolsky
Journal:  Sports Med       Date:  1994-08       Impact factor: 11.136

Review 2.  The influence of cardiovascular physiology on dose/pharmacokinetic and pharmacokinetic/pharmacodynamic relationships.

Authors:  Pietro Fagiolino; Rosa Eiraldi; Marta Vázquez
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

3.  Effects of time-release caffeine containing supplement on metabolic rate, glycerol concentration and performance.

Authors:  Adam M Gonzalez; Jay R Hoffman; Adam J Wells; Gerald T Mangine; Jeremy R Townsend; Adam R Jajtner; Ran Wang; Amelia A Miramonti; Gabriel J Pruna; Michael B LaMonica; Jonathan D Bohner; Mattan W Hoffman; Leonardo P Oliveira; David H Fukuda; Maren S Fragala; Jeffrey R Stout
Journal:  J Sports Sci Med       Date:  2015-05-08       Impact factor: 2.988

Review 4.  Clinical pharmacokinetics of non-opiate abused drugs.

Authors:  U Busto; R Bendayan; E M Sellers
Journal:  Clin Pharmacokinet       Date:  1989-01       Impact factor: 6.447

5.  The pharmacokinetics of caffeine and its dimethylxanthine metabolites in patients with chronic liver disease.

Authors:  N R Scott; D Stambuk; J Chakraborty; V Marks; M Y Morgan
Journal:  Br J Clin Pharmacol       Date:  1989-02       Impact factor: 4.335

6.  A descriptive systematic review of salivary therapeutic drug monitoring in neonates and infants.

Authors:  Laura Hutchinson; Marlene Sinclair; Bernadette Reid; Kathryn Burnett; Bridgeen Callan
Journal:  Br J Clin Pharmacol       Date:  2018-03-25       Impact factor: 4.335

7.  Inhibitory effect of grapefruit juice and its bitter principal, naringenin, on CYP1A2 dependent metabolism of caffeine in man.

Authors:  U Fuhr; K Klittich; A H Staib
Journal:  Br J Clin Pharmacol       Date:  1993-04       Impact factor: 4.335

8.  Caffeine and paraxanthine pharmacokinetics in the rabbit: concentration and product inhibition effects.

Authors:  S H Dorrbecker; R A Ferraina; B R Dorrbecker; P A Kramer
Journal:  J Pharmacokinet Biopharm       Date:  1987-04

9.  Comparative pharmacokinetics of caffeine in young and elderly men.

Authors:  J Blanchard; S J Sawers
Journal:  J Pharmacokinet Biopharm       Date:  1983-04

10.  Does long-term coffee intake reduce type 2 diabetes mellitus risk?

Authors:  Gustavo D Pimentel; Juliane Cs Zemdegs; Joyce A Theodoro; João F Mota
Journal:  Diabetol Metab Syndr       Date:  2009-09-16       Impact factor: 3.320

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.